Nantkwest (NASDAQ:NK) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04, Fidelity Earnings reports. The company had revenue of $0.01 million for the quarter. Nantkwest had a negative net margin of 164,604.89% and a negative return on equity of 44.91%.
NASDAQ:NK traded up $0.27 during trading hours on Thursday, hitting $3.26. The company’s stock had a trading volume of 359,104 shares, compared to its average volume of 746,814. The business’s 50-day moving average is $4.84 and its two-hundred day moving average is $3.13. The company has a market capitalization of $293.13 million, a PE ratio of -4.23 and a beta of 2.76. The company has a debt-to-equity ratio of 0.09, a quick ratio of 5.72 and a current ratio of 5.72. Nantkwest has a 52-week low of $0.95 and a 52-week high of $9.90.
Several analysts have recently weighed in on the stock. BidaskClub downgraded shares of Nantkwest from a “buy” rating to a “hold” rating in a report on Thursday, March 12th. ValuEngine raised Nantkwest from a “sell” rating to a “hold” rating in a report on Tuesday, March 3rd.
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Recommended Story: What is the Shanghai Stock Exchange Composite Index?
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.